CAR-T Cells in the Treatment of Malignant Hematological Tumors

NCT05619861 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell
Leukemia, B-cell
Leukemia, T-Cell
Multiple Myeloma

Interventions

BIOLOGICAL: CAR-T

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]